Aptose Bioscienc Financials
This page shows Aptose Bioscienc (APTOF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Aptose Bioscienc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Aptose Bioscienc generates $1.41 in operating cash flow (-$36.0M OCF vs -$25.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Aptose Bioscienc generated $0 in revenue in fiscal year 2024.
Aptose Bioscienc generated -$36.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 19.4% from the prior year.
Aptose Bioscienc reported -$25.4M in net income in fiscal year 2024. This represents an increase of 50.3% from the prior year.
Aptose Bioscienc earned $-36.38 per diluted share (EPS) in fiscal year 2024. This represents an increase of 84.0% from the prior year.
Aptose Bioscienc held $6.2M in cash against $0 in long-term debt as of fiscal year 2024.
Aptose Bioscienc had 2M shares outstanding in fiscal year 2024. This represents an increase of 657.7% from the prior year.
Aptose Bioscienc invested $15.1M in research and development in fiscal year 2024. This represents a decrease of 54.6% from the prior year.
Aptose Bioscienc invested $5K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 82.8% from the prior year.
APTOF Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.2M-33.1% | $3.3M+39.5% | $2.4M | N/A | $4.7M+6.5% | $4.4M-31.5% | $6.4M | N/A |
| SG&A Expenses | $2.7M-25.3% | $3.6M+17.0% | $3.1M | N/A | $2.3M-22.8% | $2.9M-11.6% | $3.3M | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | -$212K-92.7% | -$110K-31.0% | -$84K | N/A | $12K-87.1% | $93K-23.1% | $121K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.1M+27.3% | -$7.0M-27.1% | -$5.5M+28.1% | -$7.7M-10.9% | -$7.0M+4.1% | -$7.3M+24.8% | -$9.6M+19.4% | -$12.0M |
| EPS (Diluted) | $-2.01+27.2% | $-2.76-5.7% | $-2.61 | N/A | $-11.33+12.8% | $-12.99+41.0% | $-22.02 | $-1.57 |
APTOF Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.3M+13.4% | $5.6M-25.1% | $7.5M-26.3% | $10.1M-7.3% | $10.9M-0.2% | $10.9M-14.4% | $12.8M-1.5% | $13.0M |
| Current Assets | $3.8M+15.5% | $3.3M-53.1% | $7.0M-26.9% | $9.5M-6.9% | $10.2M+0.7% | $10.2M-14.1% | $11.8M-0.6% | $11.9M |
| Cash & Equivalents | $613K+10.8% | $553K-88.3% | $4.7M-22.9% | $6.2M-22.7% | $8.0M-4.4% | $8.3M+13.4% | $7.3M-20.6% | $9.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $25.8M+29.2% | $20.0M+34.3% | $14.9M+1.3% | $14.7M-26.9% | $20.1M+52.9% | $13.1M+3.7% | $12.7M-20.3% | $15.9M |
| Current Liabilities | $7.1M-21.3% | $9.0M+42.5% | $6.3M+41.1% | $4.5M-54.1% | $9.8M-23.2% | $12.7M+4.7% | $12.1M-20.5% | $15.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$19.4M-35.3% | -$14.4M-94.4% | -$7.4M-62.7% | -$4.5M+50.3% | -$9.1M-319.8% | -$2.2M-1688.3% | $137K+104.7% | -$2.9M |
| Retained Earnings | -$558.7M-0.9% | -$553.6M-1.3% | -$546.5M-1.0% | -$541.0M-0.3% | -$539.4M-1.3% | -$532.4M-1.4% | -$525.2M-1.9% | -$515.5M |
APTOF Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.4M-24.7% | -$5.9M-112.6% | -$2.8M+65.3% | -$8.1M+22.3% | -$10.4M-79.6% | -$5.8M+50.9% | -$11.8M-27.0% | -$9.3M |
| Capital Expenditures | N/A | N/A | N/A | $10K-76.2% | $42K+61.5% | $26K+8.3% | $24K | $0 |
| Free Cash Flow | N/A | N/A | N/A | -$6.2M-19.4% | -$5.2M+1.3% | -$5.3M-8.1% | -$4.9M+47.1% | -$9.3M |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0-100.0% | $2.0M+200.9% | -$2.0M-202.7% | $1.9M |
| Financing Cash Flow | $7.8M+210.0% | $2.5M+201.6% | $829K-87.8% | $6.8M-32.0% | $10.0M+110.5% | $4.8M-59.9% | $11.8M+1287.2% | $854K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
APTOF Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -80.8%+45.2pp | -126.0%-51.7pp | -74.2%-66.6pp | -7.7%+56.0pp | -63.6%+2.6pp | -66.2%+9.1pp | -75.3%+16.7pp | -92.0% |
| Current Ratio | 0.53+0.2 | 0.36-0.7 | 1.10-1.0 | 2.13+1.1 | 1.05+0.2 | 0.80-0.2 | 0.97+0.2 | 0.78 |
| Debt-to-Equity | -1.33+0.1 | -1.39+0.6 | -2.01+1.2 | -3.23-1.0 | -2.20+3.8 | -6.03-98.4 | 92.40+97.9 | -5.48 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$4.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Aptose Bioscienc's annual revenue?
Aptose Bioscienc (APTOF) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Aptose Bioscienc profitable?
No, Aptose Bioscienc (APTOF) reported a net income of -$25.4M in fiscal year 2024.
What is Aptose Bioscienc's earnings per share (EPS)?
Aptose Bioscienc (APTOF) reported diluted earnings per share of $-36.38 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Aptose Bioscienc's free cash flow?
Aptose Bioscienc (APTOF) generated -$36.0M in free cash flow during fiscal year 2024. This represents a 19.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aptose Bioscienc's operating cash flow?
Aptose Bioscienc (APTOF) generated -$36.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Aptose Bioscienc's total assets?
Aptose Bioscienc (APTOF) had $10.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Aptose Bioscienc's capital expenditures?
Aptose Bioscienc (APTOF) invested $5K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Aptose Bioscienc spend on research and development?
Aptose Bioscienc (APTOF) invested $15.1M in research and development during fiscal year 2024.
How many shares does Aptose Bioscienc have outstanding?
Aptose Bioscienc (APTOF) had 2M shares outstanding as of fiscal year 2024.
What is Aptose Bioscienc's current ratio?
Aptose Bioscienc (APTOF) had a current ratio of 2.13 as of fiscal year 2024, which is generally considered healthy.
What is Aptose Bioscienc's debt-to-equity ratio?
Aptose Bioscienc (APTOF) had a debt-to-equity ratio of -3.23 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aptose Bioscienc's return on assets (ROA)?
Aptose Bioscienc (APTOF) had a return on assets of -251.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Aptose Bioscienc's cash runway?
Based on fiscal year 2024 data, Aptose Bioscienc (APTOF) had $6.2M in cash against an annual operating cash burn of $36.0M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aptose Bioscienc's debt-to-equity ratio negative or unusual?
Aptose Bioscienc (APTOF) has negative shareholder equity of -$4.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aptose Bioscienc's Piotroski F-Score?
Aptose Bioscienc (APTOF) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aptose Bioscienc's earnings high quality?
Aptose Bioscienc (APTOF) has an earnings quality ratio of 1.41x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.